15568-86-2

Usage

Uses

Used in Organic Synthesis:
5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione is used as a reagent in organic synthesis for the formation of heterocyclic compounds, which are essential in various chemical applications.
Used in Pharmaceutical Production:
In the pharmaceutical industry, 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione is used as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and medicines.
Used in Agrochemical Production:
5-(ethoxyMethylene)-2,2-diMethyl-1,3-dioxane-4,6-dione also finds application in the agrochemical sector, where it is used in the production of pesticides and other agrochemicals to enhance crop protection and yield.
Used in Fine Chemicals Production:
5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione is utilized in the synthesis of fine chemicals, which are high-purity chemicals used in various industries, including fragrances, dyes, and specialty chemicals.
Overall, 5-(ethoxymethylene)-2,2-dimethyl-1,3-dioxane-4,6-dione plays a significant role in the advancement of organic chemistry and the development of a wide range of chemical products across different industries.

Upstream product

• 2033-24-1 cycl-isopropylidene malonate 
• 122-51-0 orthoformic acid triethyl ester 

Downstream Products

• 143618-90-0 5-<<-2-<1-(benzenesulfonyl)indolyl>>methylidene>-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 118060-66-5 5-(N-cyclohexyl-N-ethyl)-aminomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 118060-59-6 5-(N-cyclohexyl-N-isopropyl)-aminomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 118699-83-5 5-(N-cyclohexyl-N-s-butyl)aminomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 112424-55-2 5-<<(Benzyliminomethyl-λ⁶-sulfanyliden)amino>methylen>-2,2-dimethyl-1,3-dioxan-4,6-dion 
• 95079-98-4 5-<2-(<1-2H>cyclohexyl)-2-azaethylidene>-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 95079-99-5 5-<2-(<2,2,6,6-2H4>cyclohexyl)-2-azaethylidene>-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 118060-63-2 5-(N-benzyl-N-methyl)-aminomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 89044-58-6 2,2-dimethyl-5-<1-(2-methylpiperidino)methylene>-1,3-dioxane-4,6-dione 
• 155953-31-4 5-{2-[3-Ethyl-3H-benzothiazol-(2E)-ylidene]-ethylidene}-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 90367-97-8 5-[(4-Hydroxy-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-4,6-dione 
• 25063-44-9 2,2-Dimethyl-5-(p-tolylamino-methylene)-[1,3]dioxane-4,6-dione 
• 25063-47-2 2,2-dimethyl-5-(((2-nitrophenyl)amino)methylene)-1,3-dioxane-4,6-dione 
• 15568-92-0 5-(N-phenyl)-aminomethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 

Relevant academic research and scientific papers

Application of Pd-Catalyzed Cross-Coupling Reactions in the Synthesis of 5,5-Dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles that Inhibit ALK5 Kinase

C-H activation of position 3 of a substituted pyrazole ring catalyzed by palladium(II) was straightforward and convenient for arylated or heteroarylated 5,5-dimethyl-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazoles. Moreover, we introduced simple protection of the nitrogen in the pyridin-2-yl directing group, which otherwise does not allow a cross-coupling reaction, by transformation to the N-oxide. Selected final products were reasonably selective ALK5 kinase inhibitors.

A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics

Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated drug–target dockin

Development of novel quinoline-based sulfonamides as selective cancer-associated carbonic anhydrase isoform ix inhibitors

A new series of quinoline-based benzenesulfonamides (QBS) were developed as potential carbonic anhydrase inhibitors (CAIs). The target QBS CAIs is based on the 4-anilinoquinoline scaffold where the primary sulphonamide functionality was grafted at C4 of t

QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19

Disclosed herein are quinoline-based compounds and method for inhibiting CDK8 or CDK19 for the intervention in diseases, disorders, and conditions. The quinoline-based composition comprise substituents at quinoline ring positions 4 and 6, wherein the substituent at position 4 is selected from a substituted or unsubstituted arylalkylamine or a substituted or unsubstituted arylhetrocyclylamine. Pharmaceutical compositions comprising the substituted qunioline compositions, methods of inhibiting CDK8 or CDK19, and methods of treating CDK8/19-associated diseases, disorders, or conditions are also disclosed.

Vascular endothelial growth factor receptor inhibitor and preparation method and application thereof

The invention provides a vascular endothelial growth factor receptor inhibitor and a preparation method and application thereof, and relates to a quinoline or quinazoline derivative with a structure as shown in a formula (I), a pharmaceutical composition containing a compound as shown in the formula (I) and application of the compound in preparation of drugs for preventing or treating angiogenesis-related diseases, in particular to prevention or treatment of tumors related to protein tyrosine kinase. Each substituent in the formula (I) is the same as the definition in the specification.

Inhibitor IDO and application thereof (by machine translation)

The invention belongs to the technical field of medicines, and (I) particularly relates to a compound or a pharmaceutically acceptable salt, an ester, a stereoisomer, a tautomer, a ring A, a B ring R, a ring, and a ring of the compound shown in formula (I

Sulfonylurea compound as well as preparation method and application thereof

The invention discloses a sulfonylurea compound, geometrical isomers or pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, and a preparation method thereof. The sulfonylurea compound, the pharmaceutically acceptable salts, hydrates or solvates serving as active ingredients are mixed with pharmaceutically acceptable carriers or excipients to prepare compositions and preparedinto clinically acceptable dosage forms. The invention further discloses application of the compounds in preparation of medicines for treating and/or preventing proliferative diseases, application inpreparation of medicines for treating and/or preventing cancers, and application in preparation of medicines for treating and/or prostatic cancer, lung cancer and breast cancer.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel

RIP2 kinase was recently identified as a therapeutic target for a variety of autoimmune diseases. We have reported previously a selective 4-aminoquinoline-based RIP2 inhibitor GSK583 and demonstrated its effectiveness in blocking downstream NOD2 signaling in cellular models, rodent in vivo models, and human ex vivo disease models. While this tool compound was valuable in validating the biological pathway, it suffered from activity at the hERG ion channel and a poor PK/PD profile thereby limiting progression of this analog. Herein, we detail our efforts to improve both this off-target liability as well as the PK/PD profile of this series of inhibitors through modulation of lipophilicity and strengthening hinge binding ability. These efforts have led to inhibitor 7, which possesses high binding affinity for the ATP pocket of RIP2 (IC50 = 1 nM) and inhibition of downstream cytokine production in human whole blood (IC50 = 10 nM) with reduced hERG activity (14 μM).

FLUOROMALONYL HALFTHIOESTERS

The present invention relates to Fluoromalonyl Halfthioesters (F-MAHTs) of formula (I), wherein R1 represents hydrogen, halogen, an optionally substituted alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl g

Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant

Highly selective orexin receptor antagonists (SORAs) of the orexin 2 receptor (OX2R) have become attractive targets both as potential therapeutics for insomnia as well as biological tools to help further elucidate the underlying pharmacology of the orexin signaling pathway. Herein, we describe the discovery of a novel piperidine ether 2-SORA class identified by systematic lead optimization beginning with filorexant, a dual orexin receptor antagonist (DORA) that recently completed Phase 2 clinical trials. Changes to the ether linkage and pendant heterocycle of filorexant were found to impart significant selectivity for OX2R, culminating in lead compound PE-6. PE-6 displays sub-nanomolar binding affinity and functional potency on OX2R while maintaining >1600-fold binding selectivity and >200-fold functional selectivity versus the orexin 1 receptor (OX1R). PE-6 bears a clean off-target profile, a good overall preclinical pharmacokinetic (PK) profile, and reduces wakefulness with increased NREM and REM sleep when evaluated in vivo in a rat sleep study. Importantly, subtle structural changes to the piperidine ether class impart dramatic changes in receptor selectivity. To this end, our laboratories have identified multiple piperidine ether 2-SORAs, 1-SORAs, and DORAs, providing access to a number of important biological tool compounds from a single structural class.